● AI Equity Research · Healthcare

Sarepta Therapeutics, Inc. (SRPT)

AI stock analysis · Biotechnology · Last analyzed Jul 7, 2026

Compass Score

3.0/5

Call

Hold

Price

$19.51

AI Target

$22.00 +12.8%

AI Analyst Summary

Sarepta Therapeutics presents a speculative recovery thesis anchored on a dramatic forward P/E compression — from 55.7x trailing to just 7.2x forward — implying the market is pricing in a sharp earnings inflection, likely driven by the commercial ramp of its gene therapy franchise, particularly ELEVIDYS for Duchenne muscular dystrophy. With revenue currently contracting 1.9% YoY and no confirmed earnings growth trend, execution risk remains elevated and the bull case hinges entirely on near-term commercial milestones materializing as expected. The primary risk is a miss on ELEVIDYS uptake or an adverse regulatory/reimbursement development that deflates the forward earnings narrative.

Catalysts

ELEVIDYS (delandistrogene moxeparvovec) commercial ramp data in upcoming quarters — patient uptake figures and net revenue disclosures will be the single most important validation of the forward P/E compression thesis.
Potential label expansion for ELEVIDYS beyond the currently approved ambulatory patient population; a broader FDA indication could materially increase the addressable patient pool and accelerate revenue growth.
Q3/Q4 earnings reports where the forward EPS inflection is expected to begin showing in reported numbers — a confirmed beat with raised guidance could catalyze a significant re-rating from the current $19.51 price level.

Fundamentals

Pe Trailing P/E: 55.7x | Forward P/E: 7.2x · 3.0/5

Trailing P/E of 55.7x appears expensive, but the forward P/E collapsing to 7.2x signals a dramatic earnings inflection ahead. The gap between trailing and forward multiples is unusually wide, suggesting near-term profitability is expected to surge — warranting a neutral-to-constructive read pending confirmation.

Peg PEG Ratio: -0.09 · 3.0/5

A negative PEG ratio results from a negative earnings base in the trailing period, making this metric mechanically unreliable. Scored neutral pending a clean earnings baseline; the deeply discounted forward P/E is more instructive here.

Analyst Rating Hold (2.8) · 3.0/5

Consensus of 2.8 on an inverted scale (1=Strong Buy) maps to the high end of the Hold range, with 23 analysts covering the stock (6 Buy / 13 Hold / 5 Sell). Meaningful sell-side skepticism tempers enthusiasm, though coverage depth is sufficient to reflect broad market opinion.

Earnings Trend Earnings Growth YoY: N/A | Revenue Growth YoY: -1.9% · 2.0/5

YoY earnings growth is not available, and revenue contracted 1.9% — a modest but real headwind. The forward P/E compression implies expected earnings improvement, but there is no confirmed acceleration yet. The absence of positive top-line momentum warrants a below-average score.

Price Target Beat EPS Beat Rate: 3 of 4 quarters · 3.0/5

Only 4 quarters of history are available, so the full 8-quarter scoring framework cannot be applied. 3 of 4 beats is a reasonable execution record, scored neutral per the limited-history convention.

Management Mixed execution signals · 3.0/5

Management has beaten EPS estimates in 3 of the last 4 quarters, which is constructive but not exceptional. Revenue contraction and an unavailable earnings growth figure limit confidence in near-term capital allocation and commercial execution. Scored conservatively at neutral given the mixed data.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.